FY2027 Earnings Forecast for AXSM Issued By Leerink Partnrs

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Analysts at Leerink Partnrs dropped their FY2027 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a research note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of $5.90 per share for the year, down from their prior forecast of $6.45. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($5.12) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2028 earnings at $10.40 EPS.

Other equities analysts also recently issued reports about the company. Robert W. Baird boosted their price objective on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research report on Wednesday. Needham & Company LLC reiterated a “buy” rating and set a $130.00 price target on shares of Axsome Therapeutics in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 price target on shares of Axsome Therapeutics in a research note on Monday, September 16th. UBS Group cut their price objective on shares of Axsome Therapeutics from $107.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, StockNews.com lowered shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $124.93.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock traded up $0.38 during midday trading on Thursday, reaching $98.21. 24,615 shares of the stock traded hands, compared to its average volume of 618,295. Axsome Therapeutics has a fifty-two week low of $56.66 and a fifty-two week high of $105.00. The company has a current ratio of 2.44, a quick ratio of 2.40 and a debt-to-equity ratio of 1.97. The firm has a market cap of $4.66 billion, a price-to-earnings ratio of -14.98 and a beta of 1.26. The firm has a fifty day moving average price of $90.59 and a two-hundred day moving average price of $84.05.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The company had revenue of $104.76 million for the quarter, compared to analysts’ expectations of $98.71 million. During the same period last year, the business posted ($1.32) earnings per share.

Insider Buying and Selling

In other news, Director Mark E. Saad sold 11,016 shares of the stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the completion of the sale, the director now owns 10,002 shares in the company, valued at approximately $913,282.62. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.40% of the stock is currently owned by insiders.

Institutional Trading of Axsome Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. FORA Capital LLC purchased a new position in shares of Axsome Therapeutics in the third quarter worth approximately $994,000. Cynosure Group LLC acquired a new stake in Axsome Therapeutics during the 3rd quarter valued at $713,000. BNP Paribas Financial Markets raised its stake in Axsome Therapeutics by 71.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,733 shares of the company’s stock valued at $1,234,000 after purchasing an additional 5,737 shares during the period. FMR LLC lifted its holdings in shares of Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after purchasing an additional 185,951 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its position in shares of Axsome Therapeutics by 11.0% in the third quarter. Loomis Sayles & Co. L P now owns 298,586 shares of the company’s stock worth $26,834,000 after buying an additional 29,497 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.